Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer

[1]  Y. Ohe,et al.  Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab , 2018, Cancer science.

[2]  Y. Fujisaka.  Management of Immune-Related Adverse Events. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Larkin,et al.  Immune checkpoint inhibitors and cardiovascular toxicity. , 2018, The Lancet. Oncology.

[4]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Фадеев Валентин Викторович,et al.  Review of American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. , 2017 .

[6]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[7]  C. Rudin,et al.  Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. Rivkees,et al.  2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. , 2016, Thyroid : official journal of the American Thyroid Association.

[9]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[10]  P. Chanson,et al.  Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Larkin,et al.  Management of toxicities of immune checkpoint inhibitors. , 2016, Cancer treatment reviews.

[12]  A. Rossi,et al.  Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. , 2016, Current drug safety.

[13]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[14]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[16]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[17]  S. Orlov,et al.  Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. , 2015, The Journal of clinical endocrinology and metabolism.

[18]  J. Wolchok,et al.  Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. , 2014, Endocrine-related cancer.

[19]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[20]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.